Gabapentin
Product Images NDC 50436-0126

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50436-0126). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Fig 1)

A line graph showing mean pain scores over an 8-week period comparing Gabapentin 3600 mg/day with placebo. The x-axis represents weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. Gabapentin demonstrates a decreasing pain score trend, while placebo scores remain relatively stable.*

FDA Label Image

Figure 2 (Fig 2)

A line graph showing mean pain score over a 7-week period comparing placebo and Gabapentin at 1800 mg/day and 2400 mg/day doses. The x-axis represents weeks from baseline to week 7, and the y-axis shows mean pain score from 0 to 10. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3 (Fig 3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing two studies. Study 1 compares placebo (12%) to Gabapentin 3600 mg (29%), and Study 2 compares placebo (14%) to Gabapentin 1800 mg (32%) and 2400 mg (34%). Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Figure 4 (Fig 4)

A scatter plot showing the percent difference on the vertical axis against daily dose in milligrams on the horizontal axis for Gabapentin. The graph compares results from three studies labeled a, b, and c, with study a represented by black squares, study b by gray squares, and study c by white squares, illustrating differences across doses ranging approximately from 600 to 1800 mg.*

FDA Label Image

Equation 1 (Image 01)

Illustration showing the formula for calculating creatinine clearance (CLCr), involving age, weight, serum creatinine levels, and a correction factor for female patients.*

FDA Label Image

Label Image (Lbl504360126)

Gabapentin 600 mg tablet unit dose packaging label by Glenmark Pharmaceuticals, Goa, India, distributed by Unit Dose Services, LLC, Dania, FL. The label indicates a package of 30 tablets with NDC 50436-0126-1. Includes storage instructions and prescription-only designation.*

FDA Label Image

Label Image (Lbl504367210)

Gabapentin 800 mg tablet packaging label by Unit Dose Services. Each tablet contains 800 mg gabapentin USP, with 30 tablets per package. Manufactured by Glenmark Pharm Ltd, India. Includes warnings to keep out of reach of children, storage instructions at 25°C controlled room temperature, and a barcode on the label. Contains lot and expiration date placeholders.*

FDA Label Image

Glenmark Logo 2 (Logo 01)

FDA Label Image

Glenmark Logo (Logo)

FDA Label Image

Structural Formula (Structure)

Chemical structure of gabapentin showing a cyclohexane ring with amine and carboxylic acid functional groups attached.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.